“With the MIRACLE trial rapidly progressing and the first MIRACLE interim readout now clearly within reach, we believe 2026 will be a defining year for Moleculin,” said Walter Klemp, Chairman and CEO of Moleculin. “The encouraging blinded efficacy data seen so far, particularly in a pretreated population that includes venetoclax failures, reinforces our belief that Annamycin has the potential to represent a significant advancement in AML therapy.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX:
- MBRX Earnings this Week: How Will it Perform?
- Moleculin Biotech Raises Capital via Inducement Warrant Agreements
- Early Efficacy Signal in Annamycin’s Phase 3 MIRACLE Trial Supports Buy Rating on Moleculin
- Moleculin Biotech announces exercise of warrants for $8.3M gross proceeds
- Moleculin Biotech Issues New Investor Corporate Presentation